All In Biotech

Drug Trial Radar · NCT07879911

A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer

A Randomized, Open-Label, Multicenter Phase III Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Nov 30, 2028

Study completion May 30, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy. Participants may be PD-L1 negative; or PD-L1 positive with disease recurrence after PD-1/PD-L1 inhibitor therapy in the neoadjuvant/adjuvant setting; or PD-L1 positive who cannot tolerate PD-1/PD-L1 inhibitor therapy due to other underlying comorbidities. Approximately 550 participants will be enrolled and randomized at a 1:1 ratio to the experimental group or the control group. All enrolled participants will continue study treatment until BICR-confirmed disease progression, no further clinical benefit as judged by the investigator, unacceptable toxicity, withdrawal of informed consent, loss to follow-up, death, or end of study, whichever occurs first. Upon discontinuation of study treatment, participants will complete the end-of-treatment (EOT) visit and safety follow-up. Survival visits will be performed every 3 months (±14 days) after the last study drug administration to collect participants' survival status and information regarding subsequent anti-tumor therapies

Conditions

  • Triple Negative Breast Cancer

Interventions

  • Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043Biological

    Add details that will distinguish this intervention from other interventions in this or another clinical study. Participants in the experimental group will receive SYS6043, administered on Day 1 of each cycle,Q3W.

  • Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin)Drug

    Add details that will distinguish this intervention from other interventions in this or another clinical study. Paclitaxel (90 mg/m², intravenous, Days 1, 8, and 15 of each 4 week cycle \[Q4W\]; or 80 mg/m², intravenous, Days 1, 8, and 15 of each 3 week cycle \[Q3W\]); Nab paclitaxel (100 mg/m², intravenous, Days 1, 8, and 15, Q4W); Capecitabine (1000 1250 mg/m², orally, twice daily on Days 1 14, Q3W); Eribulin (1.4 mg/m², intravenous, Days 1 and 8, Q3W); Carboplatin (administered on Day 1 at an area under the curve \[AUC\] of 6, Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Assessed by BICR per RECIST 1.1Time frame: Up to approximately 5 years
  2. Overall Survival (OS)Time frame: Up to approximately 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.